K Smets1, P Vanhaesebrouck. 1. University Children's Hospital, C. Hooft, Neonatal Intensive Care Unit, Ghent, Belgium.
Abstract
UNLABELLED: To assess the role of dexamethasone treatment as a cause of systemic hypertension and associated complications, blood pressure was registered prospectively before, during and after a 4-week dexamethasone course in 22 neonates with chronic lung disease. In all patients systolic blood pressure rose significantly during treatment (median rise 34 mm Hg, range 4-->59 mm Hg), without complications attributable to hypertension. In all but one patient blood pressure returned to pretreatment values within 2 weeks after stopping dexamethasone treatment. CONCLUSION: Dexamethasone induced hypertension is transient, even after a 4-week course, and is not associated with hypertensive complications, so treatment is not necessary. When hypertension persists after dexamethasone withdrawal other causes should be considered.
UNLABELLED: To assess the role of dexamethasone treatment as a cause of systemic hypertension and associated complications, blood pressure was registered prospectively before, during and after a 4-week dexamethasone course in 22 neonates with chronic lung disease. In all patients systolic blood pressure rose significantly during treatment (median rise 34 mm Hg, range 4-->59 mm Hg), without complications attributable to hypertension. In all but one patient blood pressure returned to pretreatment values within 2 weeks after stopping dexamethasone treatment. CONCLUSION:Dexamethasone induced hypertension is transient, even after a 4-week course, and is not associated with hypertensive complications, so treatment is not necessary. When hypertension persists after dexamethasone withdrawal other causes should be considered.
Authors: B S Brozanski; J G Jones; C H Gilmour; M J Balsan; R L Vazquez; B A Israel; B Newman; F B Mimouni; R D Guthrie Journal: J Pediatr Date: 1995-05 Impact factor: 4.406
Authors: Randall D Jenkins; Julia K Aziz; Ladawna L Gievers; Harrison M Mooers; Nora Fino; David J Rozansky Journal: Pediatr Nephrol Date: 2017-07-03 Impact factor: 3.714